The evaluation of cisplatin effect on tubular function in children on chemotherapy

Pediatric Hematology and Oncology

Volumn 30, Issue 1, 2013, Pages 18-24

  Zareifar, Soheila ^a   Jafari, Hamed ^a   Geramizadeh, Bita ^b   Basiratnia, Mitra ^c   Golafshan, Habibollah ^d   Cohan, Nader ^a   Mehravar, Zahra ^a   Hamidi, Roghieh ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chemotherapy; Cisplatin; Nephrotoxicity; Tubular dysfunction

Indexed keywords

BETA 2 MICROGLOBULIN; CALCIUM; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; ETOPOSIDE; GLUCOSE; MAGNESIUM; MAGNESIUM SULFATE; MANNITOL; N ACETYL BETA GLUCOSAMINIDASE; PHOSPHORUS; PREDNISOLONE; SODIUM; SODIUM CHLORIDE; URIC ACID; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; CALCIUM URINE LEVEL; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; CREATININE URINE LEVEL; DIURESIS; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE FUNCTION; MAGNESIUM URINE LEVEL; MALE; NEPHROTOXICITY; PHOSPHATE URINE LEVEL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SIDE EFFECT; SODIUM URINE LEVEL; TUBULAR DYSFUNCTION; URIC ACID URINE LEVEL; URINALYSIS; ADOLESCENT; DRUG EFFECTS; KIDNEY TUBULE; NEOPLASMS, GERM CELL AND EMBRYONAL; NEUROBLASTOMA; PATHOPHYSIOLOGY;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CISPLATIN; FEMALE; HUMANS; KIDNEY TUBULES; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; NEUROBLASTOMA;

EID: 84872854597     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2012.737093     Document Type: Article

References (34)

1. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep. 2003;10:1663-1682
2. Galea AM, Murray V. The interaction of cisplatin and analogues with DNA in reconstituted chromatin. Biochim Biophys Acta. 2002;1579:142-15
3. Litterst CL, Torres IJ, Guarino AM. Plasma levels and organ distribution of platinum in the rat dog, and dog fish following intravenous administration of Cis-DDP (II). J Clin Hematol Oncol. 1977;7:169-172
4. Safirstein R, Miller P, Guttenplan JB. Uptake and metabolism of cisplatin by rat kidney. Kidney Int. 1984;25:753-758 (Pubitemid 14082180)
5. Dobyan DC, Levi J, Jacobs C, et al. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther. 1980;213:551-556 (Pubitemid 10085160)
6. Urakami Y, Okuda M, Masuda S, et al. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther. 1998;287:800-805 (Pubitemid 29133685)
7. Luke DR, Vadiei K, Lopez-Berestein G. Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant. 1992;7:1-7
8. Winston JA, Safirstein R. Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol. 1985;249:490-496
9. Portilla D,KaushalGP,BasnakianAG, Shah SV.Recent progress inthe pathophysiology of acute renal failure. In:Marschall S, PetersonR, PetersonC, eds. PrinciplesofMolecular Medicine. 2nded. Totowa NJ: Humana Press, Inc.; 2006;643-649
10. Xu EY, Perlina A, Vu H, et al. Integrated pathway analysis of rat urine metabolic profiles and kidney transcriptomic profiles to elucidate the systems toxicology ofmodel nephrotoxicants. Chem Res Toxicol. 2008;21:1548-1561
11. Townsend DM, DengM, Zhang L, et al.Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol. 2003;14:1-10 (Pubitemid 36026291)
12. Baliga R, Ueda N,Walker PD, Shah SV. Oxidantmechanisms in toxic acute renal failure. Drug Metab Rev. 1999;31:971-997
13. McGinness JE, Proctor PH, Demopoulos HB, et al. Amelioration of cis-platinum nephrotoxicity by orgotein (superoxide dismutase). Physiol Chem Phys. 1978;10:267-277
14. Nowak G. Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells. J Biol Chem. 2002;277:43377-43388 (Pubitemid 35285726)
15. Portilla D, Li S,Nagothu KK,Megyesi J, et al.Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int. 2006;69:2194-2204 (Pubitemid 43882106)
16. Ciarimboli G, Ludwig T, Lang D, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005;167(6):1477-1484 (Pubitemid 41713303)
17. Yonezawa A, Masuda S, Nishihara K, et al. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol. 2005;70(12):1823-1831 (Pubitemid 41612013)
18. Abdel-Gayoum AA, El-Jenjan KB, Ghwarsha KA. Hyperlipidaemia in cisplatin-induced nephrotic rats. Hum Exp Toxicol. 1999;18:454-459 (Pubitemid 29354074)
19. Li S, Wu P, Yarlagadda P, et al. PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol Renal Physiol. 2004;286:572-578
20. Negishi K,Noiri E, Sugaya T, et al. A role of liver fatty acid-binding protein in cisplatin-induced acute renal failure. Kidney Int. 2007;72:348-358 (Pubitemid 47172375)
21. de Jongh FE, van Veen RN, Veltman SJ, et al. Weekly high-dose cisplatin is a feasible treatment option: Analysis on prognostic factors for toxicity in 400 patients. Br J Cancer. 2003;88:1199- 1206 (Pubitemid 36606333)
22. Anand AJ, Bashey B. Newer insights into cisplatin nephrotoxicity. Ann Pharmacother. 1993;27:1519-1525 (Pubitemid 24005154)
23. Meyer KB,Madias NE. Cisplatin nephrotoxicity. Miner Electrolyte Metab. 1994;20:201-213 (Pubitemid 24320004)
24. Cvitkovic E, Spaulding J, Bethune V, et al. Improvement of cis-dichlorodiammineplatinum (NSC 119875): Therapeutic index in an animalmodel. Cancer. 1977;39:1357-1361 (Pubitemid 8108285)
25. Stark JJ, Howel SB. Nephrotoxicity of cis-platinum (II) dichlorodiammine. Clin Pharmacol Ther. 1978;23:461-466 (Pubitemid 8327811)
26. Erdlenbruch B, Pekrum A, Roth C, et al. Cisplatin nephrotoxicity in children after continuous 72-h and 3×1-h infusions. Pediatr Nephrol. 2001;16(7):586-593 (Pubitemid 32600165)
27. Schilsky RL, Anderson T. Hypomagnesemia and renalmagnesium wasting in patients receiving cisplatin. Ann InternMed. 1979;90:929-931 (Pubitemid 9244593)
28. Hutchison FN, Perez EA, Gandara DR, et al. Renal salt wasting in patients treated with cisplatin. Ann Intern Med. 1988;108:21-25 (Pubitemid 18081164)
29. Nanji AA, Mikhael NZ, Stewart DJ. Increase in serum uric acid level associated with cisplatin therapy. Correlation with liver but not kidney platinum concentrations. Arch Intern Med. 1985;145(11):2013-2014 (Pubitemid 16198399)
30. Halabe A,Wong NL, Sutton RA. Effect of chronic cisplatin administration on phosphate and glucose transport by the renal brush border membrane. Nephron. 1991;57(2):197-200
31. Bianchetti MG, Kanaka C, Ridolfi-Lüthy A, et al. Chronic renal magnesium loss, hypocalciuria and mild hypokalaemic metabolic alkalosis after cisplatin. Pediatr Nephrol. 1990;4:219-222 (Pubitemid 20186993)
32. Bianchetti MG, Kanaka C, Ridolfi-Lüthy A, et al. Persisting renotubular sequelae after cisplatin in children and adolescents. Am J Nephrol. 1991;11:127-130
33. Knoers NV, de Jong JC,Meij IC, et al. Genetic renal disorders with hypomagnesemia and hypocalciuria. J Nephrol. 2003;16:293-296 (Pubitemid 37304089)
34. Panichpisal K, Angulo-Pernett F, Selhi S, Nugent KM. Gitelman-like syndrome after cisplatin therapy: A ase report and literature review. BMC Nephrol. 2006;7:10